Merck KGaA to Acquire Bio-Techne for $11.3 Billion in Cash — Bio-Techne Corporation

Event summary

Merck KGaA agrees to acquire Bio-Techne for $11.3 billion (€9.9 billion) in cash, a 36% premium over Bio-Techne's average trading price.
The deal is expected to close by late 2026 or early 2027, subject to regulatory approvals and shareholder approval.
Bio-Techne brings a portfolio of cytokines, growth factors, antibodies, immunoassay kits, and ProteinSimple's automated protein detection instruments.
Merck KGaA anticipates annual cost synergies of approximately €140 million by year 3 post-closing.

The big picture

This acquisition strengthens Merck KGaA's position in high-growth areas such as multi-omics, spatial biology, cell and gene therapy, and precision diagnostics. It reflects a broader industry trend of consolidation among life sciences companies aiming to enhance their capabilities across the full spectrum of research and development workflows. The deal underscores Merck KGaA's strategy of scaling through M&A to drive innovation and expand its global reach.

What we're watching

Integration Challenges: How Merck KGaA will manage the integration of Bio-Techne's operations, given the complexity and scale of the acquisition.
Regulatory Approvals: The pace at which regulatory approvals are secured and whether any conditions are imposed that could affect the deal's timeline or terms.
Financial Performance: Whether the anticipated cost synergies of €140 million will be fully realized by year 3 post-closing and their impact on Merck KGaA's financial metrics.